엄선된 i-to-i 혁신가들이 전 세계 환자 치료를 혁신하고 있는 최신 병원 기반 AI 혁신을 소개하는 빠르게 진행되는 역동적인 발표를 다시 한번 들어보십시오.
기술, 제품, 서비스, 프로세스에 이르기까지 다양한 이러한 혁신은 지금 바로 구현 가능한 것들이며, 각각은 병원 리더들이 직면한 실제 과제를 해결하는 데 성공을 입증했습니다.
Stanford Healthcare와 협력하여 제공되는 i-to-i Innovation Hub는 대회 전반에 걸쳐 혁신을 탐구하는 목적지입니다.
Managing Director, Strategic Ventures, Stanford Medicine, USA
As Managing Director of Strategic Ventures for Stanford Medicine, Sean leads a team that incubates and operationalizes strategic priorities in areas including responsible AI in health and medicine, executive education, and global collaborations. Sean first joined Stanford Medicine in 2015 and helped lead the creation of the first Integrated Strategic Plan across the three entities comprising Stanford Medicine: Stanford School of Medicine, Stanford Health Care, and Stanford Children’s Health.
Prior to joining Stanford Medicine, Sean was an Associate Principal at McKinsey & Company in London, where he led consulting engagements with healthcare systems across Europe, particularly the NHS in England. He subsequently worked in strategy at Kaiser Permanente.
Sean earned his A.B. mcl in East Asian Studies at Harvard and M.B.A. at Harvard Business School, where he was a Baker Scholar. He also holds an MSc in International Relations from the London School of Economics and Political Science.
Professor and Chair, Stanford University School of Medicine, USA
Dr. Michael Lim is a Professor and Chair of Neurosurgery at Stanford University. Dr. Lim obtained his MD from the Johns Hopkins University School of Medicine. He then completed his residency in Neurosurgery at Stanford University Hospital and went on to become a Professor of Neurosurgery, Oncology and Radiation Oncology at Johns Hopkins before returning to Stanford as Chair. Dr. Lim’s surgical interest is in both benign and malignant brain tumors, with a particular interest in gliomas (including ependymoma), meningioma, pituitary tumors and skull base tumors. He has extensive experience in new and innovative neurosurgical techniques including image guided surgery, microsurgery, minimally invasive procedures and endoscopic surgery.
Dr. Lim’s primary research interest is developing immune-based therapies against brain tumors. His research laboratory is focused on understanding the mechanisms of immune evasion by primary brain tumors. Findings from his laboratory are directed towards translation to novel therapies against brain tumors. In addition to running a laboratory, he currently serves as the principal investigator of several large brain tumor immunotherapy clinical trials based on findings from his laboratory.
한국어
English